Increased CXCL chemokine signaling has been previously implicated in lymphoid neogenesis and COPD pathogenesis62, and a recent study demonstrated that AMD3100, a drug that inhibits the CXCL12 receptor CXCR4, reduces CS-induced emphysema in a mouse model63. This evidence concerns the gene CXCR4 and chronic obstructive pulmonary disease.